Targeting smokers at increased risk for relapse: treating women and those with a history of depression

Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at p...

Full description

Saved in:
Bibliographic Details
Published inNicotine & tobacco research Vol. 5; no. 1; p. 99
Main Authors Smith, Stevens S, Jorenby, Douglas E, Leischow, Scott J, Nides, Mitchell A, Rennard, Stephen I, Johnston, J Andrew, Jamerson, Brenda, Fiore, Michael C, Baker, Timothy B
Format Journal Article
LanguageEnglish
Published England 01.02.2003
Subjects
Administration, Cutaneous
Bupropion - administration & dosage
Depression - epidemiology
Depression - psychology
Dopamine Uptake Inhibitors - administration & dosage
Female
Humans
Male
Nicotine - administration & dosage
Recurrence
Risk Factors
Smoking - epidemiology
Smoking Cessation - methods
Smoking Cessation - statistics & numerical data
Smoking Prevention
Online AccessGet more information

Cover

More Information
Summary:Some studies have shown that female smokers and smokers with a history of depression have an increased risk of relapse following smoking cessation treatment. This study examined the efficacy of bupropion sustained-release (SR) and the nicotine patch for smoking cessation in subgroups of smokers at possible risk for relapse. Data for this study were from a previously published randomized, double-blind, placebo-controlled clinical trial in which 893 smokers were randomized to four treatment conditions: placebo tablet + placebo patch, placebo tablet + 21 mg/24-hr nicotine patch, 300mg bupropion SR + placebo patch, and 300mg bupropion SR + 21 mg/24-hr nicotine patch. Study medication continued for 8 weeks after the quit day; brief individual cessation counseling was provided during weekly clinic visits. In comparison to the placebo tablet, bupropion SR approximately tripled 1-year non-smoking rates among women and previously depressed individuals. In contrast, the nicotine patch did not significantly improve cessation rates for any group. We conclude that bupropion SR is a first-line treatment for smoking that has the potential to benefit all smokers, especially women and the previously depressed.
ISSN:1462-2203
DOI:10.1080/1462220021000060437